Cytox develops a technology platform for tests to identify individuals at risk of cognitive decline, Alzheimer’s disease and other dementias.

Research and experimental development on biotechnology.

Parallel hardware/software design.

Big data and analysis company focused on enabling reproducibility in chemistry.

DeepReason.ai offers a Knowledge Graph Management System that can integrate seamlessly with various enterprise, and public, data sources to perform fast and intelligent reasoning

Deontics is software which guides doctors and patients through the scientific and clinical decision making.

Designer Carbon Materials, Developing advanced nanomaterials for a range of applications, including energy harvesting, bio-sensing and quantum nanoelectronics.

DiffBlue is a world leader in automated test generation. Their products have been developed with industry partners over the last ten years and replace the manual process of writing tests.

A US non-profit which aims to provide education and tools for preventing public health crises and pandemics and to strengthen global public health preparedness

Company developing AI-based learning support applications.

EKB Technology commercialises a revolutionary Bioprocessing Technology developed for the use of biological systems such as plant and animal cells and microorganisms to modify, produce or purify chemical intermediates.

The company has been created by the Dementia Discovery Fund. The Company’s mission is to develop disease-modifying therapeutics that restore endo-lysosomal function and abrogate neurodegeneration in Parkinson’s disease and other dementias.

EnzBond aims to change the current understanding of enzyme evolution process.

Harnessing the power of CRISPR to develop the next generation of RNA therapeutics.

EvOx Therapeutics harnesses the body’s own precision communications system to deliver drugs to specific parts of the body, with the aim of treating conditions which are currently untreatable including those affecting the brain, as well as autoimmune diseases and cancers.

Energy from Fusion.

A new approach to automatic speech recognition technology.

Revolutionising the production of Fluorochemicals. A highly innovative, cost-effective and sustainable technology that removes the hazards of traditional fluorinating processes and supply chain.

Eykona develops state-of-the-art imaging solutions to capture dermal characteristics and shape from the human body.

G-Nostics has identified SNPs that have highly predictive associations with nicotine addiction and therefore tobacco consumption. These SNPs provide a method to help individuals decide which specific smoking cessation methods are most effective for them, offering personalised treatment to the 'smoker' which significantly increases their chances of quitting.